Esthesioneuroblastoma other imaging findings: Difference between revisions
Simrat Sarai (talk | contribs) No edit summary |
Simrat Sarai (talk | contribs) No edit summary |
||
| Line 2: | Line 2: | ||
__NOTOC__ | __NOTOC__ | ||
{{Esthesioneuroblastoma}} | {{Esthesioneuroblastoma}} | ||
{{CMG}}{{AE}}{{Simrat} | {{CMG}}{{AE}}{{Simrat}} | ||
==Overview== | ==Overview== | ||
==Other Imaging Findings== | ==Other Imaging Findings== | ||
Revision as of 18:11, 19 January 2016
|
Esthesioneuroblastoma Microchapters | |
|
Diagnosis | |
|---|---|
|
Treatment | |
|
Case Studies | |
|
Esthesioneuroblastoma other imaging findings On the Web | |
|
American Roentgen Ray Society Images of Esthesioneuroblastoma other imaging findings | |
|
Risk calculators and risk factors for Esthesioneuroblastoma other imaging findings | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Simrat Sarai, M.D. [2]
Overview
Other Imaging Findings
Other imaging studies for esthesioneuroblastoma include angiography/digital subtraction angiography and nuclear medicine.
Angiography/Digital subtraction angiography (DSA)
Angiography demonstrates a prominent tumour blush with arteriovenous shunting, and persistent opacification.
Nuclear Medicine
As with other neuroblastomas, olfactory neuroblastomas are -meta-iodobenzylguanidine, MIBG avid. This potentially helps to differentiate them from other tumors that arise in the region.